Solventum SOLV · NYSE
$85.10 -0.83% (-$0.71)
Summary
67 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 17 USD is left as net profit.
- You pay 10.1 USD for 1 USD of yearly profit, little for its sector.
- It earns 16 USD a year on every 100 USD of invested capital.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- Revenue grew by only 0.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 10.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 0.8% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 1.1%. Earnings per share grew by 4.5% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 45 USD
- Research and development 8.7 USD
- Sales and administration 21 USD
- Taxes and other 7.7 USD
- Net profit 17 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 17 USD is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 2
- Sell 1
Today's price within the analysts' price targets
The average target of $91.22 is 7.2% above today's price. 75% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 100%
By region
- UNITED STATES 56%
- Non-US 44%
Product brings in 100% of revenue.
Segments in detail